The lancet oncology
-
The lancet oncology · Mar 2015
Review Practice GuidelineOptimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014.
Supportive care and palliative care are now recognised as critical components of global cancer control programmes. Many aspects of supportive and palliative care services are already available in some low-income and middle-income countries. Full integration of supportive and palliative care into breast cancer programmes requires a systematic, resource-stratified approach. ⋯ The panel consensus statements were published in October, 2013. This Executive Summary combines the three panels' recommendations into a single comprehensive document covering breast cancer care from diagnosis through curative treatment into survivorship, and metastatic disease and end-of-life care. The recommendations cover physical symptom management, pain management, monitoring and documentation, psychosocial and spiritual aspects of care, health professional education, and patient, family, and caregiver education.
-
The lancet oncology · Mar 2015
Randomized Controlled Trial Multicenter Study Comparative StudyHypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
In 2007, we began the randomised phase 3 multicentre HYPRO trial to investigate the effect of hypofractionated radiotherapy compared with conventionally fractionated radiotherapy on relapse-free survival in patients with prostate cancer. Here, we examine whether patients experience differences in acute gastrointestinal and genitourinary adverse effects. ⋯ The Dutch Cancer Society.
-
The lancet oncology · Mar 2015
Multicenter StudyActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer. ⋯ Bristol-Myers Squibb.
-
The lancet oncology · Mar 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Pre-transplantation (18)F-fluorodeoxyglucose (FDG) PET-negativity is one of the strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relapsed or refractory Hodgkin's lymphoma. In this study, we assessed the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE). ⋯ Seattle Genetics.
-
The lancet oncology · Mar 2015
Morphogenetic fields of embryonic development in locoregional cancer spread.
The ontogenetic theory of locoregional cancer spread regards cancer as a clinical manifestation of the pathological reactivation and maintenance of the sequential developmental programmes that previously controlled the stepwise embryological morphogenesis of the tissue from which the cancer originated. In the state of morphostasis that characterises adult organisms, these programmes are silenced. During malignant progression, these programmes run in retrograde sequence, which leads to cancer infiltration of ever larger tissue areas. ⋯ The theory can be tested morphologically and clinically for all tumours. Verification of this theory would offer substantial potential to improve prognostic assessment and surgical treatment. Identification of the complementary positional information for tumour cells in different ontogenetic stages, and their associated cancer fields, could be a molecular research strategy to further test the theory.